Top

Published in:

01-11-2009 | Review

Mammary field cancerization: molecular evidence and clinical importance

Authors: Christopher M. Heaphy, Jeffrey K. Griffith, Marco Bisoffi

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

The term “field cancerization” originally denoted the presence of histologically abnormal tissue/cells surrounding primary tumors of the head and neck. Similar concepts with different and continuously changing definitions have been used for other types of tumors including breast adenocarcinoma, where field cancerization presently denotes the occurrence of molecular alterations in histologically normal tissues surrounding areas of overt cancer. Human mammary tissue morphology lends itself to the proposed concepts of field cancerization, which may include the gradual accumulation of genetic and other aberrations in stationary epithelial cells with intact morphology, or the spread of histologically normal yet genetically aberrant epithelial cells within mammary tissue. In this report, we review published molecular genetic, epigenetic, and gene expressional data in support of field cancerization in human mammary tissues. We then discuss the clinical implications of mammary field cancerization, including its source for potential biomarkers with diagnostic/prognostic potential, and its relationship to surgical margins and disease recurrence. We conclude with a future outlook on further research on mammary field cancerization addressing experimental methods, as well as the development of possible models and integrated approaches to gain a better understanding of the underlying mechanisms with the ultimate goal of developing clinical applications.

Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963–968CrossRefPubMed

Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL (2007) Clinical implications and utility of field cancerization. Cancer Cell Int 7:2CrossRefPubMed

Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727–1730PubMed

Hockel M, Dornhofer N (2005) The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res 65:2997–3002PubMed

Lim W, Park EH, Choi SL, Seo JY, Kim HJ, Chang MA, Ku BK, Son B, Ahn SH (2009) Breast conserving surgery for multifocal breast cancer. Ann Surg 249:87–90CrossRefPubMed

Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomark Prev 8:855–861

Jain S, Rezo A, Shadbolt B, Dahlstrom JE (2009) Synchronous multiple ipsilateral breast cancers: implications for patient management. Pathology 41:57–67CrossRefPubMed

Coyle YM (2004) The effect of environment on breast cancer risk. Breast Cancer Res Treat 84:273–288CrossRefPubMed

Huston TL, Simmons RM (2005) Locally recurrent breast cancer after conservation therapy. Am J Surg 189:229–235CrossRefPubMed

10.

Radisky ES, Radisky DC (2007) Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 8:279–287CrossRefPubMed

11.

Fukino K, Shen L, Matsumoto S, Morrison CD, Mutter GL, Eng C (2004) Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 64:7231–7236CrossRefPubMed

12.

Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA (2000) Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60:2562–2566PubMed

13.

Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson PH, Eng C (2001) Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 10:1907–1913CrossRefPubMed

14.

Fukino K, Shen L, Patocs A, Mutter GL, Eng C (2007) Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. Jama 297:2103–2111CrossRefPubMed

15.

O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703CrossRefPubMed

16.

Larson PS, de las Morenas A, Cerda SR, Bennett SR, Cupples LA, Rosenberg CL (2006) Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. J Pathol 209:307–316CrossRefPubMed

17.

Heaphy CM, Bisoffi M, Joste NE, Baumgartner KB, Baumgartner RN, Griffith JK (2008) Genomic instability demonstrates similarity between DCIS and invasive carcinomas. Breast Cancer Res Treat. doi:10.1007/s10549-008-0165-4

18.

Larson PS, de las Morenas A, Cupples LA, Huang K, Rosenberg CL (1998) Genetically abnormal clones in histologically normal breast tissue. Am J Pathol 152:1591–1598PubMed

19.

Larson PS, de las Morenas A, Bennett SR, Cupples LA, Rosenberg CL (2002) Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 161:283–290PubMed

20.

Larson PS, Schlechter BL, de las Morenas A, Garber JE, Cupples LA, Rosenberg CL (2005) Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. J Clin Oncol 23:8613–8619CrossRefPubMed

21.

Heaphy CM, Bisoffi M, Fordyce CA, Haaland CM, Hines WC, Joste NE, Griffith JK (2006) Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer 119:108–116CrossRefPubMed

22.

Forsti A, Louhelainen J, Soderberg M, Wijkstrom H, Hemminki K (2001) Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer 37:1372–1380CrossRefPubMed

23.

Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD (2004) Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol 5:753–758CrossRefPubMed

24.

Ellsworth DL, Ellsworth RE, Love B, Deyarmin B, Lubert SM, Mittal V, Shriver CD (2004) Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas. Breast Cancer Res Treat 88:131–139CrossRefPubMed

25.

Ellsworth RE, Ellsworth DL, Lubert SM, Hooke J, Somiari RI, Shriver CD (2003) High-throughput loss of heterozygosity mapping in 26 commonly deleted regions in breast cancer. Cancer Epidemiol Biomark Prev 12:915–919

26.

Ellsworth DL, Ellsworth RE, Love B, Deyarmin B, Lubert SM, Mittal V, Hooke JA, Shriver CD (2004) Outer breast quadrants demonstrate increased levels of genomic instability. Ann Surg Oncol 11:861–868CrossRefPubMed

27.

Botti C, Pescatore B, Mottolese M, Sciarretta F, Greco C, Di Filippo F, Gandolfo GM, Cavaliere F, Bovani R, Varanese A, Cianciulli AM (2000) Incidence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: an interphase cytogenetic study. J Am Coll Surg 190:530–539CrossRefPubMed

28.

Desmaze C, Soria JC, Freulet-Marriere MA, Mathieu N, Sabatier L (2003) Telomere-driven genomic instability in cancer cells. Cancer Lett 194:173–182CrossRefPubMed

29.

Bohr VA, Anson RM (1995) DNA damage, mutation and fine structure DNA repair in aging. Mutat Res 338:25–34PubMed

30.

Olovnikov AM (1971) Principle of marginotomy in template synthesis of polynucleotides. Doklady Akademii nauk SSSR 201:1496–1499PubMed

31.

Smogorzewska A, van Steensel B, Bianchi A, Oelmann S, Schaefer MR, Schnapp G, de Lange T (2000) Control of human telomere length by TRF1 and TRF2. Mol Cell Biol 20:1659–1668CrossRefPubMed

32.

Meeker AK, Hicks JL, Gabrielson E, Strauss WM, De Marzo AM, Argani P (2004) Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol 164:925–935PubMed

33.

Meeker AK, Argani P (2004) Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia 9:285–296CrossRefPubMed

34.

Kurabayashi R, Takubo K, Aida J, Honma N, Poon SS, Kammori M, Izumiyama-Shimomura N, Nakamura KI, Tsuji EI, Matsuura M, Ogawa T, Kaminishi M (2008) Luminal and cancer cells in the breast show more rapid telomere shortening than myoepithelial cells and fibroblasts. Human Pathol 39:1647–1655CrossRef

35.

Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, Sukumar S, Parsons R, Richardson AL, Stampfer MR, Gelman RS, Nikolskaya T, Nikolsky Y, Polyak K (2008) Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci USA 105:14076–14081CrossRefPubMed

36.

Friso S, Choi SW (2002) Gene-nutrient interactions and DNA methylation. J Nutr 132:2382S–2387SPubMed

37.

Seitz HK, Stickel F (2007) Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev 7:599–612CrossRef

38.

Li S, Hursting SD, Davis BJ, McLachlan JA, Barrett JC (2003) Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann N Y Acad Sci 983:161–169CrossRefPubMed

39.

Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan MB, Sun ZW, Mernaugh RL, Parl FF (2007) Carcinogen-induced histone alteration in normal human mammary epithelial cells. Carcinogenesis 28:2184–2192CrossRefPubMed

40.

Kanai Y (2008) Alterations of DNA methylation and clinicopathological diversity of human cancers. Pathol Int 58:544–558CrossRefPubMed

41.

Dworkin AM, Huang TH, Toland AE (2009) Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 19:165–171CrossRefPubMed

42.

Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH (2006) Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 12:6626–6636CrossRefPubMed

43.

Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang TH (2008) Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 68:1786–1796CrossRefPubMed

44.

Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S (2001) Hypermethylation of 14–3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20:3348–3353CrossRefPubMed

45.

Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, McDermott K, Kozakiewicz K, Gauthier ML (2004) Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 9:263–274CrossRefPubMed

46.

Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG, Tlsty TD (2003) Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63:1596–1601PubMed

47.

Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM (2005) Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 11:166–172PubMed

48.

Braakhuis BJ, Leemans CR, Brakenhoff RH (2004) Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice. J Pathol 203:620–621CrossRefPubMed

49.

Finak G, Sadekova S, Pepin F, Hallett M, Meterissian S, Halwani F, Khetani K, Souleimanova M, Zabolotny B, Omeroglu A, Park M (2006) Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 8:R58CrossRefPubMed

50.

Tripathi A, King C, de la Morenas A, Perry VK, Burke B, Antoine GA, Hirsch EF, Kavanah M, Mendez J, Stone M, Gerry NP, Lenburg ME, Rosenberg CL (2008) Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. Int J Cancer 122:1557–1566CrossRefPubMed

51.

Baird DM (2008) Mechanisms of telomeric instability. Cytogenet Genome Res 122:308–314CrossRefPubMed

52.

Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15:50–65CrossRefPubMed

53.

Hines WC, Fajardo AM, Joste NE, Bisoffi M, Griffith JK (2005) Quantitative and spatial measurements of telomerase reverse transcriptase expression within normal and malignant human breast tissues. Mol Cancer Res 3:503–509CrossRefPubMed

54.

Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA, Shay JW (1996) Telomerase activity in human breast tumors. J Natl Cancer Inst 88:116–122CrossRefPubMed

55.

Liu J, Baykal A, Fung KM, Thompson-Lanza JA, Hoque A, Lippman SM, Sahin A (2004) Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. Int J Oncol 24:879–884PubMed

56.

Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL (1998) Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 19:182–186CrossRefPubMed

57.

Kyo S, Takakura M, Fujiwara T, Inoue M (2008) Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 99:1528–1538CrossRefPubMed

58.

Sawyers CL (2008) The cancer biomarker problem. Nature 452:548–552CrossRefPubMed

59.

Paci E, Warwick J, Falini P, Duffy SW (2004) Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen 11:23–27CrossRefPubMed

60.

Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418:823CrossRefPubMed

61.

Cancer KleinCA (2008) The metastasis cascade. Science 321:1785–1787 New York, NYCrossRef

62.

Robson ME (2007) Treatment of hereditary breast cancer. Semin Oncol 34:384–391CrossRefPubMed

63.

Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P (2005) Towards discovery-driven translational research in breast cancer. FEBS J 272:2–15CrossRefPubMed

64.

Ottewell PD, Coleman RE, Holen I (2006) From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat 96:101–113CrossRefPubMed

65.

Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101:4966–4971CrossRefPubMed

Title: Mammary field cancerization: molecular evidence and clinical importance
Authors: Christopher M. Heaphy
Jeffrey K. Griffith
Marco Bisoffi
Publication date: 01-11-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0504-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk

Cancer stem cells in breast cancer and metastasis

Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease

Three-dimensional scapulothoracic motion following treatment for breast cancer

Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer